Skip to main content

Table 3 Main HBs amino-acid changes observed in treated and untreated patients

From: Epidemiological, virological and clinical characteristics of HBV infection in 223 HIV co-infected patients: a French multi-centre collaborative study

HBs amino-acid changes Overall HBV active treatment p
   Never Ongoing Stopped  
Y100 10 (4.9%) 1 (2.6%) 5 (4.6%) 4 (7.0%) 0.59
S114 113 (52.6%) 16 (41.0%) 60 (53.7%) 37 (58.7%) 0.22
T118 6 (2.7%) 1 (2.5%) 4 (3.4%) 1 (1.5%) 0.75
T125 27 (12.4%) 4 (10.3%) 15 (13.2%) 8 (12.3%) 0.89
T126 3 (1.4%) 0 1 (0.9%) 2 (3.1%)0 0.33
P127 71 (32.7%) 19 (50.0%) 34 (29.6%) 18 (28.1%) 0.04
T131 131 (59.5%) 16 (41%) 75 (64.1%) 40 (62.5%) 0.03
M133 4 (1.8%) 1 (2.5%) 3 (2.6%) 0 0.427
Y134 170 (78.3%) 34 (85.0%) 82 (73.2%) 54 (83.1%) 0.16
T140 51 (23.1%) 16 (41.0%) 21 (17.9%) 14 (21.5%) 0.012
S143 116 (53%) 15 (38.5%) 63 (55.3%) 38 (59.4%) 0.10
D144 5 (2.3%) 2 (5.0%) 3 (2.7%) 0 0.24
G145 6 (2.8%) 1 (2.6%) 5 (4.3%) 0 0.25
  1. Absolute number and percentage in parentheses for the considered population are represented.